In response to your captioned letter dated 02.12.2025, we would like to state that we have reviewed and verified the relevant internal records, operations and developments and hereby confirm ....
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt has replied to a BSE email dated 2 December 2025 seeking clarification on unusual trading volume in its shares. The company stated it has reviewed all internal records, operations, and developments, and confirmed there is no undisclosed information, pending announcement, or event that could explain the price/volume movement under SEBI Listing Regulations. The company reiterated that it disseminates all price-sensitive information within statutory timelines and will continue to comply with Regulation 30 disclosure obligations.
This is a routine 'no undisclosed information' response to a stock exchange surveillance query, so there is no material impact on shareholders. However, the exchange's query itself signals that trading volumes were abnormal, which may keep the stock under short-term scrutiny.